What the FDA labels say about taking them together
Insulin glargine and somatropin
Insulin glargine's FDA label of June 16, 2026 names somatropin in its drug interactions section; somatropin's label does not name insulin glargine itself but warns about its class (insulin analogs). The insulin glargine label: “… niacin, oral contraceptives, phenothiazines, progestogens, protease inhibitors, somatropin, sympathomimetic agents, and thyroid hormones. …”
Check it at the source: the insulin glargine FDA label on DailyMed (effective June 16, 2026, Eli Lilly and Company); the somatropin FDA label on DailyMed (effective August 20, 2026, Eli Lilly and Company).
What does the insulin glargine label say about somatropin?
Insulin glargine label, drug interactionsDrugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs.
Source: FDA drug label (Insulin Glargine, BLA761201), Biocon Biologics Inc., effective January 23, 2026 (SPL set 3ac85ebb-5594-59c8-77fd-df254329d151), via openFDA
Source: FDA drug label (Lantus Solostar, BLA021081), sanofi-aventis U.S. LLC, effective June 2, 2025 (SPL set d5e07a0c-7e14-4756-9152-9fea485d654a), via openFDA
Source: FDA drug label (Toujeo, BLA206538), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set c9561d96-124d-48ca-982f-0aa1575bff36), via openFDA
Source: FDA drug label (BASAGLAR KwikPen), Eli Lilly and Company, effective June 16, 2026 (SPL set 0ad21db3-2b1c-4ed9-a687-bdd6a74d0aae), via openFDA; the full label on DailyMed
What does the somatropin label say about insulin glargine?
Somatropin's label does not name insulin glargine itself; it warns about its class (insulin analogs):
Somatropin label, drug interactionsInsulin and/or Other Hypoglycemic Agents
Somatropin label, drug interactionsTreatment with HUMATROPE may decrease insulin sensitivity, particularly at higher doses.
Source: FDA drug label (HUMATROPE), Eli Lilly and Company, effective August 20, 2026 (SPL set a774e1ae-3997-49ee-8b0e-99a2b315d409), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Insulin glargine | Somatropin | |
|---|---|---|
| Labeled for | Type 2 diabetes, Type 1 diabetes | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $2.90 per mL 100 pen | $752.22 per cartridge 5 mg cartridge |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once